GSK plc (LSE:GSK) is a British multinational pharmaceutical and biotechnology company founded in 1715, making it one of the world's oldest pharmaceutical companies. The company was formed through a series of mergers, most notably the 2000 merger of Glaxo Wellcome and SmithKline Beecham, and changed its name from GlaxoSmithKline plc to GSK plc in May 2022. Headquartered in Brentford, United Kingdom, GSK has evolved from a traditional pharmaceutical company into a focused biopharmaceutical enterprise specializing in vaccines and specialty medicines. The company operates globally with significant presence in the United States, Europe, and emerging markets, dedicating its efforts to preventing and treating diseases through innovative research and development.
$48.39
−0.72%Price chart
Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29
Key dataOct 29, 2026
Open$48.19
From 52W high−20.91%
Volume3.50M
Market cap$96.95B
P/E (TTM)15.1x
P/S (TTM)2.2x
Div yield3.75%
Key dataOct 29, 2026
Open
$48.19
From 52W high
−20.91%
Volume
3.50M
Market cap
$96.95B
ValuationView details →
P/E (Fwd)
9.4x
EV/EBITDA
9.9x
P/E (TTM)
15.1x
RSI (14)
45.4
MomentumView details →
1D Return
−0.72%
YTD Return
−1.22%
SummaryUpdated Jun 1, 2026
Latest newsMore news →
GSK plc reported third-quarter adjusted earnings of $1.47 per share, or 54.6 pence, while specialty-drug sales grew by double digits and vaccine sales declined.1d agoGSK plc reported quarterly earnings of $1.47 per share, above the Zacks Consensus Estimate of $1.40 and compared with $1.48 per share a year earlier.1d agoGSK plc shares fell after weaker vaccine sales were reported.1d ago